News Focus
News Focus
Followers 6
Posts 969
Boards Moderated 0
Alias Born 03/01/2012

Re: marzan post# 445602

Wednesday, 02/04/2026 2:47:34 PM

Wednesday, February 04, 2026 2:47:34 PM

Post# of 446819
I think we're actually closer than it may sound. I agree that buying Hikma doesn't undo generic entry, and that Hikma being in play increases the odds of settlement or licensing - that part makes sense.
Where I still differ is on necessity and timing. With 50%+ market share, Amarin still has leverage and optionality, and I don't see the incentive to pre-emptively cap upside via a royalty or sale path before that leverage is resolved. Settlement can happen without forcing Amarin into a structural endgame.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News